Gilead Sciences Inc. (GILD): Price and Financial Metrics

Gilead Sciences Inc. (GILD): $72.31

0.21 (+0.29%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add GILD to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#7 of 360

in industry

GILD Price/Volume Stats

Current price $72.31 52-week high $87.86
Prev. close $72.10 52-week low $71.37
Day low $72.04 Volume 5,401,100
Day high $72.66 Avg. volume 7,629,764
50-day MA $78.63 Dividend yield 4.16%
200-day MA $77.62 Market Cap 90.08B

GILD Stock Price Chart Interactive Chart >

GILD POWR Grades

  • Value is the dimension where GILD ranks best; there it ranks ahead of 97.5% of US stocks.
  • The strongest trend for GILD is in Stability, which has been heading down over the past 26 weeks.
  • GILD ranks lowest in Momentum; there it ranks in the 10th percentile.

GILD Stock Summary

  • With a market capitalization of $104,019,577,395, GILEAD SCIENCES INC has a greater market value than 97.59% of US stocks.
  • GILEAD SCIENCES INC's stock had its IPO on January 22, 1992, making it an older stock than 83.02% of US equities in our set.
  • In terms of volatility of its share price, GILD is more volatile than merely 0.99% of stocks we're observing.
  • Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are ADI, NTES, BMY, PYPL, and TXN.
  • GILD's SEC filings can be seen here. And to visit GILEAD SCIENCES INC's official web site, go to www.gilead.com.

GILD Valuation Summary

  • GILD's price/sales ratio is 3.7; this is 11.9% lower than that of the median Healthcare stock.
  • GILD's EV/EBIT ratio has moved up 81.6 over the prior 243 months.

Below are key valuation metrics over time for GILD.

Stock Date P/S P/B P/E EV/EBIT
GILD 2023-12-29 3.7 4.5 17.2 14.7
GILD 2023-12-28 3.7 4.5 17.2 14.7
GILD 2023-12-27 3.7 4.5 17.0 14.6
GILD 2023-12-26 3.6 4.5 17.0 14.5
GILD 2023-12-22 3.6 4.4 16.9 14.5
GILD 2023-12-21 3.6 4.4 16.7 14.3

GILD Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -60.73%.
  • Its 5 year net cashflow from operations growth rate is now at -41.74%.
  • The 5 year net income to common stockholders growth rate now stands at -60.73%.
Over the past 34 months, GILD's revenue has gone up $4,565,000,000.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 27,281 9,072 4,592
2022-09-30 27,136 9,710 3,334
2022-06-30 27,515 10,100 4,137
2022-03-31 27,472 10,614 4,515
2021-12-31 27,305 11,384 6,225
2021-09-30 27,482 10,095 7,394

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
  • ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.406 0.805 0.259
2021-06-30 0.402 0.801 0.179
2021-03-31 0.405 0.806 0.066
2020-12-31 0.403 0.815 0.058
2020-09-30 0.389 0.790 0.058
2020-06-30 0.375 0.786 0.009

GILD Price Target

For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.84 Average Broker Recommendation 1.7 (Moderate Buy)

Gilead Sciences Inc. (GILD) Company Bio


Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).


GILD Latest News Stream


Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream


Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.

The 500 Top Stocks to Buy for 2024, Ranked by AI

These are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system.

Thomas Yeung on InvestorPlace | December 29, 2023

Here's Why Gilead Sciences (NASDAQ:GILD) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | December 28, 2023

The 30 Happiest Cities in America in 2023

In this article, we will take a look at the 30 happiest cities in America in 2023. If you want to skip our discussion on the impact of residence on well-being, you can go directly to The 5 Happiest Cities in America in 2023. Despite the common belief that money can’t buy happiness, one cannot deny […]

Yahoo | December 28, 2023

12 Best Stocks to Buy for an 18 Year Old

In this article, we discuss the 12 best stocks to buy for an 18 year old. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Stocks to Buy for an 18 Year Old. It is an exciting time to be involved in trading stocks. The Federal Reserve in […]

Yahoo | December 28, 2023

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.

Yahoo | December 27, 2023

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -6.04%
3-mo -6.86%
6-mo -1.96%
1-year -7.36%
3-year 29.50%
5-year 37.42%
YTD -10.74%
2023 -1.99%
2022 23.63%
2021 29.95%
2020 -6.70%
2019 7.88%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!